Viking Therapeutics Inc. has detailed its latest advancements in the development of novel therapeutics for metabolic and endocrine diseases. The company highlighted its clinical programs, including VK2735, a dual GLP-1/GIP agonist for obesity, which successfully achieved its primary endpoint in the VENTURE Phase 2 obesity study, with a Phase 3 study planned for the second quarter of 2025. Additionally, the VK2735 oral version has completed Phase 2 enrollment after demonstrating positive proof of concept and weight reduction in Phase 1. For NASH/MASH, VK2809, a selective thyroid receptor-β agonist, successfully completed the VOYAGE Phase 2b trial, meeting primary and secondary endpoints. In the rare disease domain, VK0214, another thyroid receptor-β agonist, showed proof of concept in reducing key biomarkers in X-ALD patients during Phase 1b studies. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.